| Recruiting | MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers NCT06911008 | Mayo Clinic | Phase 1 |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refra NCT06620302 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Studying TAK-243 in Patients With Advanced Cancer NCT06223542 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Meta NCT06320405 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMA NCT05554341 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease NCT05791448 | University of Southern California | Phase 1 |
| Active Not Recruiting | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors NCT05286801 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment NCT05455606 | SWOG Cancer Research Network | N/A |
| Recruiting | AOH1996 for the Treatment of Refractory Solid Tumors NCT05227326 | City of Hope Medical Center | Phase 1 |
| Suspended | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic NCT05111561 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ an NCT06400264 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors NCT05038839 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944 | Children's Oncology Group | Phase 1 / Phase 2 |
| Active Not Recruiting | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors NCT05071209 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Unknown | Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors NCT04981691 | Ruijin Hospital | Phase 1 |
| Recruiting | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You NCT04500548 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer NCT04294628 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tum NCT04530487 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Pati NCT04197713 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors NCT04266912 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors NCT03878095 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations NCT04233567 | Sameek Roychowdhury | Phase 2 |
| Active Not Recruiting | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol NCT06400251 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Sub NCT06400225 | National Cancer Institute (NCI) | Phase 2 |
| Completed | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors NCT03756818 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification NCT03253679 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H NCT06400238 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapse NCT03420963 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MAT NCT06308822 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) NCT05490771 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | FID-007 in Treating Participants With Advanced Solid Tumors NCT03537690 | University of Southern California | Phase 1 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors NCT03366103 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tu NCT03430882 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A NCT06385483 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors NCT03320330 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or L NCT03323034 | Children's Oncology Group | Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or NCT03065387 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patient NCT02975882 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification NCT06390839 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) NCT04439227 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subp NCT06385496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z NCT06390852 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATC NCT06390865 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02808650 | Children's Oncology Group | Phase 1 |
| Completed | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol NCT06390826 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol NCT06357975 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MAT NCT06360575 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification ( NCT04439201 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subproto NCT04439214 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) NCT04439123 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol NCT04439344 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) NCT04439240 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N NCT04439149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotoco NCT04439188 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelio NCT02535312 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subp NCT04439357 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1 NCT04439318 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-S NCT04439175 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) NCT04439305 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer NCT02671890 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant NCT06357988 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) NCT06303167 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subp NCT04439331 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) NCT04439136 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G NCT04439253 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R NCT04439279 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATC NCT04439292 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) NCT04439266 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATC NCT04439110 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors NCT02079740 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors NCT01709435 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies NCT01364051 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma NCT01303341 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymp NCT00939770 | Children's Oncology Group | Phase 1 / Phase 2 |